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Abstract
Background: Peritoneal dialysis (PD) technique survival is an important outcome for patients, caregivers and health
professionals, however, the definition and measures used for technique survival vary. We aimed to assess the scope and
consistency of definitions and measures used for technique survival in studies of patients receiving PD.
Method: MEDLINE, EMBASE and CENTRAL databases were searched for randomised controlled studies (RCTs)
conducted in patients receiving PD reporting technique survival as an outcome between database inception and
December 2019. The definition and measures used were extracted and independently assessed by two reviewers.
Results: We included 25 RCTs with a total of 3645 participants (41–371 per trial) and follow up ranging from 6 weeks
to 4 years. Terminology used included ‘technique survival’ (10 studies), ‘transfer to haemodialysis (HD)’ (8 studies)
and ‘technique failure’ (7 studies) with 17 different definitions. In seven studies, it was unclear whether the definition
included transfer to HD, death or transplantation and eight studies reported ‘transfer to HD’ without further definition
regarding duration or other events. Of those remaining, five studies included death in their definition of a technique event,
whereas death was censored in the other five. The duration of HD necessary to qualify as an event was reported in only
four (16%) studies. Of the 14 studies reporting causes of an event, all used a different list of causes.
1 School of Medicine, Keele University, Newcastle, UK
2 Department of Nephrology, Princess Alexandra Hospital, Brisbane,
Australia
3 Australasian Kidney Studies Network, The University of Queensland,
Brisbane, Australia
4 Translational Research Institute, Brisbane, Australia
5 Department of Renal Medicine, Auckland City Hospital, Auckland, New
Zealand
6 Polycystic Kidney Disease International, Geneva, Switzerland
7 Polycystic Kidney Disease Charity, London, UK
8 Department of Medicine, The University of Hong Kong, Queen Mary
Hospital, Hong Kong
9 Department of Medicine, Western University, London, Ontario,
Canada
10 Botucatu School of Medicine, University of Sao Paulo State—UNESP,
Brazil
11 Clinical Innovation and Business Unit, South Western Sydney Local
Health District, Sydney, Australia
12 Faculty of Nursing, University of Sydney, Sydney, Australia
13 UNSW Faculty of Medicine, University of New South Wales, Sydney,
Australia
14 School of Health Science, University of Tasmania, Hobart, Australia
15 Maisonneuve-Rosemont Research Centre and Hospital, Montreal,
Canada
16 The Kidney and Transplant Practice, Mount Elizabeth Novena Hospital,
Singapore
17 Medical School, University of Western Australia, Crawley, Australia
18 Sydney School of Public Health, University of Sydney and Centre for
Kidney Research, The Children’s Hospital at Westmead, Sydney,
Australia
19 Division of Nephrology, St Michael’s Hospital and the Keenan Research
Centre in the Li Ka Shing Knowledge Institute, St Michael’s Hospital,
University of Toronto, Ontario, Canada
Corresponding author:










Conclusion: There is substantial heterogeneity in how PD technique survival is defined and measured, likely contributing
to considerable variability in reported rates. Standardised measures for reporting technique survival in PD studies are
required to improve comparability.
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Introduction
Transfer from peritoneal dialysis (PD) to haemodialysis
(HD) increases the risk of mortality1 and healthcare costs
by about threefold at 3 years2 when compared to continuing
of PD. While national and international registries show
marked variability in the rates of transfer to HD across cen-
tres,3,4 approximately one-third of the patients on PD will
transfer to HD within 5 years of commencing PD.5 Percep-
tions of technique survival may affect modality selection
decisions and clinician perceptions of the value of the mod-
ality. The Standardised Outcomes in Nephrology-Peritoneal
Dialysis (SONG-PD) initiative, based on the shared priori-
ties of patients, caregivers and health professionals,
identified technique survival as a critically important
core outcome to be reported in all studies in patients receiv-
ing PD.6
Despite the importance of this outcome, the terminol-
ogy used in the literature is not consistent, with technique
failure and technique survival both used. Both of these
terms produce ambiguity in the events that comprise the
outcome, particularly with respect to death. The SONG-
PD process recommended technique survival as the pre-
ferred terminology to avoid the negative connotation of
technique failure, although this leaves it unclear how to
refer to specific events.
There is no widely accepted definition available for
technique survival or transfer to HD. Important considera-
tions in the definition include whether stopping PD is suf-
ficient or if the use of HD is required, the duration of HD
required, whether transplantation, death or recovery of kid-
ney function are included, and the population to which this
definition should be applied. Indeed, variability in the dura-
tion of HD required has already been shown to affect the
reported rate of technique survival. For example, according
to an analysis of the Australia and New Zealand Dialysis
and Transplant (ANZDATA) registry, the rate of patients
returning to PD by 1 year was 24% using the definition of
minimum HD duration of 30 days, compared to 3% when
180 days were used.7 Furthermore, causes of transfer to HD
are varied, including peritonitis, patient choice and catheter
problems, and no consensus exists on the recording or
reporting of cause-specific transfer to HD across studies.8
The aim of this study was to assess the scope and varia-
bility of the definitions of technique survival used in PD
studies and to assess the different methodologies used to
report rates and risk factors for transfer to HD. This was to
better inform the development of a standardised measure
for technique survival in PD, a necessary step to ensure
consistent reporting of outcomes to enable direct compar-
isons of the effect of interventions across studies, thereby
improving research efficiency, decreasing research waste
and accurately informing decision making for all stake-
holders, including patients, caregivers and clinicians.
Methods
Terminology
We used technique survival when discussing the outcome
generally, the actual event (death, transfer to HD) when
necessary for clarity and technique failure only when this
was the specific term used in the included articles.
Search and selection criteria
The study review protocol was registered with PROS-
PERO9 and conforms to the Preferred Reporting Items for
Systematic reviews and Meta-Analyses checklist.10 Studies
eligible were randomised controlled studies (RCTs) report-
ing technique survival as an outcome or adverse event. All
interventions were included. Patients aged 18 years or over
who were currently or previously on PD for at least 1 day
were included in the analysis. Studies not published in
English and observational studies were excluded.
MEDLINE, EMBASE and the Cochrane Central Regis-
ter of Controlled Trials (CENTRAL) were searched from
database inception (1964, 1947 and not applicable due to
composite nature, respectively) to December 2019, with the
search strategy provided in Supplementary Material. Med-
ical subject headings and free-text terms for PD, continuous
ambulatory PD, continuous cyclic PD, technique failure,
technique survival and transfer to HD were combined with
the search filter for RCTs. Titles and abstracts were
screened by two of three assigned reviewers (EE and MT
or MH) with studies excluded if they did not meet the
inclusion criteria. The full manuscripts of potentially eligi-
ble studies were then reviewed by two reviewers (EE and
MT or MH) for inclusion. Any disagreement was resolved
through discussion and by a third reviewer if necessary.
Data extraction
Data extraction into a standardised spreadsheet was com-
pleted by two reviewers independently (EE and MT or
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MH), with each entry cross checked and inconsistencies
discussed until resolved. In the case of multiple publica-
tions of a study, these were highlighted and grouped.
Authors of articles were contacted if needed for clarifica-
tions regarding additional unpublished data.
Study setting, population and demographics were col-
lected alongside the number of participants randomised and
analysed, inclusion criteria (first PD episode or any PD
episode, PD within a certain duration of kidney replace-
ment therapy (KRT) commencement, inclusion from the
start of KRT or from the defined time period after the start
of KRT), country (or centre/s) and the number of events.
Definitions recorded were PD start (catheter insertion, start
or end of training and exchange for solute clearance) and
definition of technique survival/technique failure/transfer
to HD (duration of HD required, inclusion or censoring
of other events, such as death or transplantation). Results
extracted were the measure used (rate/probability/time to
event), value reported with standard deviation and/or stan-
dard error/confidence interval, missing data and rates of
loss to follow up. Reasons for transfer to HD were sum-
marised as: if reported (y/n), list of reasons included, num-
ber of reasons allowed (one or more) and proportion of
events by reason. Administrative censoring rates, if
reported, were included alongside death, transplant and
recovery of kidney function rates and measures used. Miss-
ing data were coded as missing.
Results
Study characteristics
From the 200 articles retrieved, 25 studies were included
(Figure 1), of which 2 were multinational and 13 were
multicentre with 12 single centres. Four studies included
children and adults.11–14 No studies included children only.
All included studies were parallel-design RCTs, where var-
ious interventions were examined: eight studies of PD solu-
tion (16–18, 24, 26–29 and 1022 participants), one study of
PD modality (chronic ambulatory PD vs. continuous cyclic
PD) (14 and 82 participants), eight studies of type of cathe-
ter/connector (11–13, 15, 19, 22, 30, 32 and 1360 partici-
pants), four studies of exit site treatment (20–21, 31, 35 and
781 participants), one study of timing of commencement of
PD (25 and 122 participants), one study of subcutaneous
implantation of PD catheter (23 and 59 participants), one
study of the number of dialysate exchanges (34 and 139
participants) and one study of treatment of peritonitis (33
and 80 participants).
The year of publication ranged from 1994 and 2019. The
follow up time ranged from 6 weeks to 4 years with a
median follow up time from 3 months to 34 months. The
median number of total participants in the studies was 145,
ranging from 41 to 371 with 3645 participants over all
studies. (Table 1) Technique survival was a secondary out-
come in 20 studies (11, 13, 15–17, 19–26, 28, 30–35 and
2970 participants), included in a list of outcomes in three
studies, where the primary outcome was not clear (12, 14,
29 and 223 participants) and listed as an outcome in two
articles, which were secondary analyses of studies (18, 27
and 452 participants).
Thirteen studies included ‘incident’ PD patients only
(11–12, 14–15, 17–19, 24, 26–27, 29, 32, 34 and 1460
participants), with two studies stating, ‘new to PD’ (28 and
86 participants) or ‘starting CAPD’ (23 and 59 partici-
pants). Three studies specified prevalent only (16, 22, 35
and 852 participants), whereas seven studies included both
incident and prevalent PD patients (13, 20–21, 25, 30–31,
33 and 1188 participants). In studies with prevalent
patients, one study specified a duration of KRT of over
6 weeks as inclusion criteria (16 and 118 participants). The
other studies did not specify incident/prevalent patients as
an inclusion criterion (Table 2). No studies defined the start
of PD, apart from two studies, where time between PD
catheter insertion and usage was part of the intervention
(23, 25 and 181 participants).
Definitions of technique survival
Three different terms were used for the outcome, with
‘technique survival’ in 10 studies (11–12, 16–17, 19, 24,
26–27, 29, 32 and 1112 participants), ‘transfer to HD’ in
eight studies (14–15, 20–21, 23, 28, 31, 33 and 777 parti-
cipants) and ‘technique failure’ in seven studies (13, 18, 22,
25, 30, 34, 35 and 1756 participants). These three terms had
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Figure 1. Flowchart for data extraction and reasons for exclu-
sion of studies.
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outcome with 17 different definitions in total. Transfer to
HD was included in the definition in all studies. When the
terminology used was ‘transfer to HD’, it was assumed but
not explicitly stated that death was censored in all the stud-
ies. In studies using the technique survival/failure terminol-
ogy, the outcome included death as an event in five studies
(12, 16, 22, 26, 30 and 950 participants), it was a censoring
event in five studies (11, 13, 19, 24, 27 and 902 partici-
pants) and it was not explicit how it was treated in the
remaining seven studies. Transplantation was a censoring
event in nine studies (11–13, 16, 19, 22, 26–27, 30 and
1706 participants) although it was not explicit that it was
censored in the remaining 16 studies (Table 2). One study
included changing from the randomised treatment alloca-
tion to the comparator (change in PD disconnect system
from carex to ultra) as an event in the outcome ‘technique
failure’ (22 and 363 participants).
Four studies reported a minimum duration of HD to
define a transfer to HD: 30 days (2 studies, 214 partici-
pants),11,19 ‘continued HD until end of follow up’ (1 study,
101 participants),26 ‘any duration of HD’ (1 study, 371
participants).34 Two studies defined transfer to HD as ‘per-
manently transferred’ without further definition (2 studies,
166 participants).13,28 The remaining 19 studies did not
specify a minimum duration of HD. In seven studies (17,
18, 25, 29, 32, 34–35 and 1016 participants), it was unclear
what criteria were used to define transfer to HD.
Reporting of technique survival
The percentage or number of events included in the defi-
nition of technique survival were reported in 22 studies
(11–12, 14–24, 26, 28–35 and 2948 participants) although
the follow up period varied and rates were not provided in
any study. Twenty-two studies (11–22, 24–27, 29–30, 32–
35 and 3354 participants) compared technique survival
rates between the intervention and control arms, of which
21 used time to event analysis (11–22, 24–27, 29–30, 32,
34–35 and 3274 participants) and 1 used odds ratio (33 and
60 participants), while the remaining three studies were
unclear how technique survival was evaluated (23, 28, 31
and 291 participants).
The causes of transfer to HD were reported in 16 of 25
studies (Table 3) (11, 14–15, 17–19, 23, 25–26, 28–30,
32–35 and 1933 participants). The most commonly reported
cause for transferring to HD was peritonitis, which was
reported in 14 of these 16 studies (11, 14–15, 17–18, 23,
26, 28–30, 32–35 and 1679 participants). Of these studies,
one study specified ‘persistent elevation of effluent white
cell count, fungal infection or fungal superinfection’ (33 and
80 participants), six studies specified relapsing/recurrent/
refractory/prolonged peritonitis (11, 14–15, 26, 29, 34 and
472 participants), one study reported ‘PD related infection’
(35 and 371 participants), while the remaining six studies
reported only ‘peritonitis’ as a cause (17, 18, 23, 28, 30, 32
and 756 participants). Additionally, three studies specified














The Netherlands 2 (8)
South Korea 2 (8)
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Mean follow up time
<1 year 2 (8)
1 to <2 years 10 (40)
2 to 3 years 9 (36)








APD and CAPD 14 (56)
Adults/paediatrics
Adults only 15 (60)
Adults and paediatrics 5 (20)
Not reported 5 (20)
Type of intervention
Type of solution 8 (32)
Type of PD catheter/connector 8 (32)
PD exit site treatment 4 (16)
Timing of commencement of PD 2 (8)
Subcutaneous implantation of PD catheter 1 (4)
Treatment of peritonitis 1 (4)
PD modality 1 (4)
HD: haemodialysis; PD: peritoneal dialysis; CAPD: continuous ambulatory
peritoneal dialysis; APD: automated peritoneal dialysis.











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































exit site infection (11, 15, 23 and 168 participants) and one
study specified tunnel infection (18 and 185 participants),
but it was not clear in other studies how exit site infections
were classified. One study specified ‘catheter-associated
infection’ (19 and 132 participants) without specifying
whether this included peritonitis.
Two studies reported only peritonitis-related transfers to
HD without mentioning other causes (30, 34 and 407 par-
ticipants), with the remaining 14 studies having a different
list of reasons in each case (11, 14–19, 23, 25–26, 28–29,
32–33, 35 and 1644 participants). ‘Ultrafiltration failure’ or
‘poor ultrafiltration’ was reported in two studies (14, 26,
183 participants) with one study specifying ‘volume excess
caused by insufficient ultrafiltration’ (29 and 41 partici-
pants), a further four studies instead reported ‘inadequate
solute clearance’ (17–19, 35 and 766 participants) without
further elaboration and one stated insufficient dialysis.34
Fluid overload was reported alongside inadequate solute
clearance in one study (35, 371 participants).
Discussion
Despite the critical importance of technique survival in PD,
a SONG-PD core outcome and the primary outcome for the
largest PD study to date (The Peritoneal Dialysis Outcomes
and Practice Patterns Study P-DOPPS),36 our study demon-
strates it remains inconsistently defined and reported in
RCTs of PD patients. There was substantial variability in
the reported outcome, including in its definition (transfer to
HD with or without death), minimum duration of HD
required, the terminology used by researchers and clini-
cians, the population to which it is applied, the definition
of PD start, reasons given for the event and the exact mea-
sures used.
A key constituent of the definition of technique survival
is the duration of HD required to qualify as a transfer to
HD, and an ANZDATA registry analysis of the impact of
differences in this demonstrated a longer survival time with
longer duration of HD used in the definition (median tech-
nique survival time of 2.0 years using 30 days compared
with 2.4 years using 365 days).7 This difference is partly
due to the likelihood of returning to PD, which was much
higher with the 30-day (24%) compared to the 180-day
(3%) definition.7 This demonstrates that the definition used
will affect the reported results. Only six of the studies iden-
tified in this review reported how the duration of HD was
used to define technique survival, using four different
approaches, with some using unclear definitions or insuffi-
cient detail to allow for meaningful comparison of results
between studies.
While a transfer to HD had been commonly used to
define technique survival, whether mortality is included
in the definition significantly impacts the rates reported.
The Registre de Dialyse Peritoneale de Langue Francaise37
reports transfers to HD and death separately, whereas the
ANZDATA registry reports technique survival as a com-
posite of transfers to HD and death,38 in addition to ‘Death-
censored technique failure’. Defining technique survival as
transfer to HD with, or without death, provides different
perspectives as including death will highlight the impact of
co-morbidity but excluding death may highlight differ-
ences in practice patterns. Such heterogeneity in the
approach to defining technique survival will likely make
a large difference in reported rates. For example, in a recent
UK Renal Registry analysis assessing PD patients 1 year
after the commencement of therapy, 14% of PD patients
had transferred to HD, 5% had died and 10% had been
transplanted.39 Given the difference in its definition
between registries, the heterogeneity identified in our study
about whether death contributed to the definition of tech-
nique survival was not surprising. However, in the 15 stud-
ies using the terminology of technique survival/failure,
limited reporting of events contributing to the outcome
leaves significant uncertainty about the exact interpretation
of technique survival.
Transferring to HD is a complex event with numerous
potential causes, which can co-exist, and the relative con-
tribution of these varies with the duration of PD.40 Further-
more, any differences in transfers to HD in RCTs are likely
to be driven by large changes in one or two of the possible
causes, for example, changes in peritonitis rate, rather than
a smaller overall reduction in all possible causes. The over-
lap between the different recorded causes in these studies
was unclear, such that it was not possible to compare causes
Table 3. List of causes for transfer to HD.a
Cause of transfer to HD
Number of
studies (%)
Peritonitis/PD related infection 15 (60)
Inadequate solute clearance/under dialysed/
insufficient dialysis
8 (32)
Catheter-related infection 5 (20)




Psychosocial/unable to cope 3 (12)
Cerebrovascular accident 2 (8)
Pleuroperitoneal communication 2 (8)
Dialysate leak 2 (8)
Other 2 (8)
Inguinal hernia 2 (8)
Major abdominothoracic surgery 1 (4)
Poor compliance 1 (4)
Total blindness 1 (4)
Patient preference 1 (4)
Multiple problems 1 (4)
Persistent hypercalcaemia 1 (4)
Gastric cancer 1 (4)
Genital leakage 1 (4)
Congestive cardiac failure 1 (4)
Fluid overload 1 (4)
HD: haemodialysis; PD: peritoneal dialysis.
aCause for transfer to HD reported in 16 of 25 studies.
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for transferring between studies. Efforts should be made to
standardise how the causes of transfers to HD are defined.
Technique survival has been shown to vary with the
duration of PD, with a higher event rate earlier in the treat-
ment course.37,39,40 The population included, whether inci-
dent or prevalent, will therefore potentially affect the
reported rate of technique survival, so reasonable compar-
isons of technique survival rates require accurate reporting
of the study population. To achieve this would require both
a comparable definition for start date (e.g. catheter inser-
tion date, commencement of training or exchanges to
improve solute clearance) and clear definitions of inci-
dent/prevalent status using minimum/maximum time on
PD, which was only mentioned in three studies. This again
highlights the complexity in trying to compare different
studies with limited information on study methodology.
Limitations of this study included the possibility of pub-
lication bias, although it is unlikely that this would directly
affect the definitions of technique survival used. Observa-
tional studies and registry reports were not included, as this
was likely to lead to an unmanageable increase in the num-
ber of studies included, while RCTs not reported in English
were also excluded, although this made no difference to the
results. Children were not included in this review, but this
was to avoid duplication in the literature. A previous
review did not find technique survival as a reported out-
come in studies of this population.41
Technique survival is an important outcome from the
point of view of both health economic and patient out-
comes, emphasising the need to identify and understand
interventions that can improve this outcome. These results
demonstrate the difficulties in understanding and compar-
ing the impact of interventions on technique survival when
standardised reporting and outcomes are not used. This
work represents an important first step in the SONG-PD
technique survival work stream, helping to develop stan-
dardised definition and reporting of technique survival in
all PD studies, and highlights the need to consider issues
such as the need for a standardised time on HD to be
accepted as an event, and whether a range of outcomes may
be necessary for different studies, while ensuring the results
are accessible to patients. Furthermore, if consistent report-
ing of technique survival can be applied across both studies
and registries, this will facilitate quality improvement
attempts to address the marked variability found between
and within countries.
Acknowledgement
The authors would like to acknowledge the contribution to the
discussion by Dr Robert R Quinn.
Author contributions
ML, DWJ, SJD, KEM, AT and NB conceived and designed the
study. EE, MH and MT performed the search, screening and data
extraction. EE wrote the first draft of the manuscript. All authors
reviewed and edited the manuscript and approved the final version
of the manuscript.
Declaration of conflicting interests
The author(s) declared the following potential conflicts of interest
with respect to the research, authorship, and/or publication of this
article: ML has received honoraria from Fresenius Medical Care,
Baxter Healthcare and NxStage and a research grant from Baxter
Healthcare. DJ has received consultancy fees, research grants,
speaker’s honoraria and travel sponsorships from Baxter Health-
care and Fresenius Medical Care, as well as consultancy fees from
AWAK and Astra Zeneca, speaker’s honoraria from Ono and
travel sponsorships from Amgen. He is a current recipient of an
Australian National Health and Medical Research Council
(NHMRC) Practitioner Fellowship. JP has received speaking hon-
oraria from Astra Zeneca, Baxter Healthcare, DaVita Healthcare
Partners, Fresenius Medical Care, Dialysis Clinics Incorporated,
Satellite Healthcare, and has served as a consultant for Baxter
Healthcare, DaVita Healthcare Partners, Fresenius Medical Care,
and LiberDi. NB has received unrestricted educational grants,
travel grants or honoraria from Baxter Healthcare, Amgen, Astra
Zeneca, Roche Pharmaceuticals and FMC. YC has received
research grants and speaker’s honoraria from Baxter Healthcare
and research grants from Fresenius Medical Care and Amgen. She
is a current recipient of an Australian NHMRC Early Career
Fellowship. AYW has received grants from Baxter Corporation
and Sanofi Renal and received speaker honorarium from Frese-
nius Kabi and Sanofi Renal. AL has received speaker’s honoraria
from Baxter Healthcare. JC has previously received speaker’s
honoraria and research funds from Baxter Healthcare, Fresenius
Medical Care, Roche Pharmaceuticals and Amgen. AKJ has
received consultancy fees, research grants, speaker’s honoraria
from Baxter Healthcare and AWAK Technologies. ACNF has
received research grants from Baxter Healthcare and scholarship




The author(s) received no financial support for the research,









Simon J Davies https://orcid.org/0000-0001-5127-4755
Mark Lambie https://orcid.org/0000-0002-6285-5368
Supplemental material
Supplemental material for this article is available online.
Elphick et al. 7
References
1. Woodrow G, Turney JH and Brownjohn AM. Technique fail-
ure in peritoneal dialysis and its impact on patient survival.
Perit Dial Int 1997; 17(4): 360–364.
2. Chui BK, Manns B, Pannu N, et al. Health care costs of
peritoneal dialysis technique failure and dialysis modality
switching. Am J Kidney Dis 2013; 61(1): 104–111.
3. van de Luijtgaarden MWM, Jager KJ, Segelmark M, et al.
Trends in dialysis modality choice and related patient sur-
vival in the ERA-EDTA registry over a 20-year period.
Nephrol Dial Transplant 2016; 31(1): 120–128.
4. Schaubel DE, Blake PG and Fenton SS. Effect of renal center
characteristics on mortality and technique failure on perito-
neal dialysis. Kidney Int 2001; 60(4): 1517–1524.
5. Huisman RM, Nieuwenhuizen MGM and Th de Charro F.
Patient-related and centre-related factors influencing tech-
nique survival of peritoneal dialysis in The Netherlands.
Nephrol Dial Transplant 2002; 17(9): 1655–1660.
6. Manera KE, Johnson DW, Craig JC, et al. Establishing a core
outcome set for peritoneal dialysis: report of the standardized
outcomes in nephrology – peritoneal dialysis (SONG-PD)
consensus workshop. Am J Kidney Dis 2020; 75(3): 404–412.
7. Lan PG, Clayton PA, Johnson DW, et al. Duration of hemo-
dialysis following peritoneal dialysis cessation in Australia
and new Zealand: proposal for a standardized definition of
technique failure. Perit Dial Int 2016; 36(6): 623–630.
8. Davies SJ, Phillips L, Griffiths AM, et al. What really hap-
pens to people on long-term peritoneal dialysis? Kidney Int
1998; 54(6): 2207–2217.
9. Elphick E. Outcome measures for technique failure reported
in peritoneal dialysis: a systematic review 2018. http://www.
crd.york.ac.uk/PROSPERO/display_record.php?ID¼CRD
42018092641 (accessed 12 March 2021).
10. Moher D, Shamseer L, Clarke M, et al. Preferred reporting
items for systematic review and meta-analysis protocols
(PRISMA-P) 2015 statement. Syst Rev 2015; 4: 1.
11. Cheng IKP, Chan CY, Cheng SW, et al. A randomized pro-
spective study of the cost-effectiveness of the conventional
spike, O-set, and UVXD techniques in continuous ambula-
tory peritoneal dialysis. Perit Dial Int 1994; 14(3): 255–260.
12. Ong L-M, Lim T-O, Hooi L-S, et al. A randomized, multi-
center, open-label trial to establish therapeutic equivalence
between the Carex and ultra disconnect systems in patients on
continuous ambulatory peritoneal dialysis. Peri Dial Int
2003; 23 Suppl 2: S139–S143.
13. Wong H-S, Ong L-M, Lim T-O, et al. A randomized, multi-
center, open-label trial to determine peritonitis rate, product
defect, and technique survival between ANDY-Disc and
UltraBag in patients on CAPD. Am J Kidney Dis 2006;
48(3): 464–472.
14. Zhang L, Badve SV, Pascoe EM, et al. The effect of exit-site
antibacterial honey versus nasal mupirocin prophylaxis on the
microbiology and outcomes of peritoneal dialysis-associated
peritonitis and exit-site infections: a sub-study of the honey-
pot trial. Perit Dial Int 2015; 35(7): 712–721.
15. Banin VB, Ponce D, Dias DB, et al. Influence of the intra-
peritoneal segment of the swan neck peritoneal catheter on
infectious and mechanical complications and technique sur-
vival. Clin Exp Nephrol 2019; 23: 135–141.
16. Chow KM, Wong SSM, Ng JKC, et al. Straight versus coiled
peritoneal dialysis catheters: a randomized controlled trial.
Am J Kidney Dis 2020; 75: 39–44.
17. De Fijter CWH, Oe LP, Nauta JJP, et al. Clinical efficacy and
morbidity associated with continuous cyclic compared with
continuous ambulatory peritoneal dialysis. Ann Intern Med
1994; 120(4): 264–271.
18. Eklund B, Honkanen E, Kyllönen L, et al. Peritoneal dialysis
access: prospective randomized comparison of single-cuff
and double-cuff straight Tenckhoff catheters. Nephrol Dial
Transplant 1997; 12(12): 2664–2666.
19. Fan SLS, Pile T, Punzalan S, et al. Randomized controlled
study of biocompatible peritoneal dialysis solutions: effect on
residual renal function. Kidney Int 2008; 73(2): 200–206.
20. Farhat K, Douma CE, Ferrantelli E, et al. Effects of conver-
sion to a bicarbonate/lactate-buffered, neutral-pH, low-GDP
PD regimen in prevalent PD: a 2-year randomized clinical
trial. Perit Dial Int 2017; 37(3): 273–282.
21. Johnson DW, Brown FG, Clarke M, et al. The effects of
biocompatible compared with standard peritoneal dialysis
solutions on peritonitis microbiology, treatment, and out-
comes: The balANZ trial. Perit Dial Int 2012; 32(5):
497–506.
22. Johnson DW, Wong J, Wiggins KJ, et al. A randomized
controlled trial of coiled versus straight swan-neck Tenckhoff
catheters in peritoneal dialysis patients. Am J Kidney Dis
2006; 48(5): 812–821.
23. McQuillan RF, Chiu E, Nessim S, et al. A randomized con-
trolled trial comparing mupirocin and polysporin triple oint-
ments in peritoneal dialysis patients: the MP3 study. Clin J
Am Soc Nephrol 2012; 7(2): 297–303.
24. Nunez-Moral M, Sanchez-Alvarez E, Gonzalez-Diaz I, et al.
Exit-site infection of peritoneal catheter is reduced by the use
of polyhexanide. Results of a prospective randomized trial.
Peri Dial Int 2014; 34(3): 271–277.
25. Park MS, Yim AS, Chung SH, et al. Effect of prolonged
subcutaneous implantation of peritoneal catheter on peritoni-
tis rate during CAPD: a prospective randomized study. Blood
Purif 1998; 16(3): 171–178.
26. Park SH, Do JY, Kim YH, et al. Effects of neutral pH and
low-glucose degradation product-containing peritoneal dialy-
sis fluid on systemic markers of inflammation and endothelial
dysfunction: a randomized controlled 1-year follow-up study.
Nephrol Dial Transplant 2012; 27(3): 1191–1199.
27. Ranganathan D, Baer R, Fassett RG, et al. Randomised Con-
trolled Trial to determine the appropriate time to initiate peri-
toneal dialysis after insertion of catheter to minimise
complications (timely PD study). BMC Nephrol 2010;
11(1): 11.
28. Sikaneta T, Wu G, Abdolell M, et al. The trio trial - a rando-
mized controlled clinical trial evaluating the effect of a
8 Peritoneal Dialysis International XX(X)
biocompatible peritoneal dialysis solution on residual renal
function. Perit Dial Int 2016; 36(5): 526–532.
29. Srivastava S, Hildebrand S and Fan SLS. Long-term follow-
up of patients randomized to biocompatible or conventional
peritoneal dialysis solutions show no difference in peritonitis
or technique survival. Kidney Int 2011; 80(9): 986–991.
30. Stein A, Baker F, Moorhouse J, et al. Peritonitis rate: tradi-
tional versus low calcium dialysate. Am J Kidney Dis 1995;
26(4): 632–633.
31. Takatori Y, Akagi S, Sugiyama H, et al. Icodextrin increases
technique survival rate in peritoneal dialysis patients with
diabetic nephropathy by improving body fluid management:
a randomized controlled trial. Clin J Am Soc Nephrol 2011;
6(6): 1337–1344.
32. Wong P-N, Tong GMW, Wong Y-Y, et al. Alternating mupir-
ocin/gentamicin is associated with increased risk of fungal
peritonitis as compared with gentamicin alone - results of a
randomized open-label controlled trial. Perit Dial Int 2016;
36(3): 340–346.
33. Xie J, Kiryluk K, Ren H, et al. Coiled versus straight perito-
neal dialysis catheters: a randomized controlled trial and
meta-analysis. Am J Kidney Dis 2011; 58(6): 946–955.
34. Xu R, Yang Z, Qu Z, et al. Intraperitoneal vancomycin plus
either oral moxifloxacin or intraperitoneal ceftazidime for the
treatmentofperitonealdialysis-relatedperitonitis:a randomized
controlled pilot study. Am J Kidney Dis 2017; 70(1): 30–37.
35. Yan H, Fang W, Lin A, et al. Three versus 4 daily exchanges
and residual kidney function decline in incident CAPD
patients: a randomized controlled trial. Am J Kidney Dis
2017; 69(4): 506–513.
36. Perl J, Davies SJ, Lambie M, et al. The peritoneal dialysis
outcomes and practice patterns study (PDOPPS): unifying
efforts to inform practice and improve global outcomes in
peritoneal dialysis. Perit Dial Int 2016; 36(3): 297–307.
37. Castrale C, Evans D, Verger C, et al. Peritoneal dialysis in
elderly patients: report from the French Peritoneal Dialysis
Registry (RDPLF). Nephrol Dial Transplant 2010; 25(1):
255–262.
38. Htay H, Cho Y, Pascoe EM, et al. Center effects and
peritoneal dialysis peritonitis outcomes: analysis of a
national registry. Am J Kidney Dis 2018; 71: 814–821. Epub
2017.
39. Tabinor M, Casula A, Wilkie M, et al. UK renal registry 19th
annual report: chapter 13 home therapies in 2015: national
and centre-specific analyses. Nephron 2017; 137(Suppl 1):
297–326.
40. Kolesnyk I, Dekker FW, Boeschoten EW, et al. Time-
dependent reasons for peritoneal dialysis technique failure
and mortality. Perit Dial Int 2010; 30(2): 170–177.
41. Chong LSH, Sautenet B, Tong A, et al. Range and hetero-
geneity of outcomes in randomized trials of pediatric chronic
kidney disease. J Paediatr 2017; 186: 110–117.
Elphick et al. 9
